Short term clinical efficacy and safety of ticagrelor in patients received percutaneous coronary intervention
10.3969/j.issn.1004-8812.2014.06.010
- VernacularTitle:替格瑞洛用于经皮冠状动脉介入治疗术后患者抗血小板治疗短期内的有效性和安全性研究
- Author:
Yingyan MA
;
Yanxia WANG
;
Baige XU
;
Na LI
;
Guanghua HUANG
;
Cailian WANG
;
Yi FANG
;
Yaling HAN
- Publication Type:Journal Article
- Keywords:
Stenting;
Percutaneous coronary intervention;
Ticagrelor
- From:
Chinese Journal of Interventional Cardiology
2014;(6):380-383
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efifcacy and safety of ticagrelor in patients received percutaneous coronary intervention (PCI). Methods 50 patients with non-responding platelet aggregation rate and CYPC219 gene after clopidogrel treatment were given ticagrelor and enrolled in the study. All enrolled patients received aspirin loading dosage 300 mg, followed by maintenance dosage 100 mg, once daily and ticagrelor maintenance dosage 90 mg twice daily, for 1 year. The primary endpoint for the study were the incidence of major cardiovascular events (including death, stent thrombosis, stent restenosis, nonfatal myocardial infarction, target vessel revascularization) and stroke after followed up for a month. The secondary endpoint were the incidence of general events (including minor bleeding, allergies, breathing dififculties) and platelet count changes. Results No occur major cardiovascular and stroke events record after 1 month of ticagrelor treatment. The general events rates included 2 cases of dyspnen, 1 case of epitaxis and 1 case of subcutaneous bleeding. The platelet aggregation with ticagrelor was signiifcantly lower than clopidogrel without signiifcant decrease in platelets count. Conclusions Using ticagrelor for antiplatelet in patients with coronary artery stenting in clopidogrel resistance cases is safe and effective.
